/https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/3d0bbff304382f7323a52cddb9243d14.jpg)
Historical Medicine
OBOMEDIA ENTERTAINMENT
The 40% of volunteers dropped from analysis that made the drug seem to work
NOV 21, 202612 MIN
/https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/45678591538ea440da8a4414ba806962.jpg)
Description
A lead researcher deleted 40% of volunteer data after the blind broke, threatening an Alzheimer’s drug trial-how did that happen?
The 40% of volunteers dropped from analysis that made the drug seem to work
In this episode, we lay out the timeline and people behind the simufilam Phase 2 trial and the contested data handling that followed Cassava Sciences' September 2020 announcement. We track decisions, credentials, and the scientific record to ask how the data changed and who knew what when.
Person: Lindsay H. Burns
Company: Cassava Sciences
Drug: simufilam
Event: Phase 2 results announcement
Date: September 2020
- Burns led the trial and had an Olympic silver medal, a Cambridge PhD, and decades of neuroscience publications.
- Cassava announced statistically significant improvements in September 2020 and the stock rose after the press release.
- Forty percent of volunteer data was removed from the analysis after the researcher knew who received drug versus placebo.
- Burns collaborated with Hoau-Yan Wang on the FLNA hypothesis and published multiple papers between 2008 and 2017.
- Several related papers were later retracted or carry expressions of concern, altering the published foundation for the drug.
Tired of ads? Listen to this podcast and 200+ more ad-free on OBOMEDIA.
Try it free for 7 days, cancel anytime: https://obomedia.com/en/gratis?ref=desc-7317668
© 2026 Created by an independent creator of the OBOMEDIA Network. All rights reserved.
This episode and its content (audio, text, and related materials) are the property of their respective creator, who is solely responsible for them, and are distributed by the OBOMEDIA Network on platforms such as Apple Podcasts, Spotify, Amazon Music, and Pocket Casts. Reproduction, distribution, editing, or commercial use, in whole or in part, without the creator's prior written permission is prohibited. For permissions, licensing, and business inquiries: [email protected].

